Hologic Announces Financial Results for Third Quarter of Fiscal 2024

Rhea-AI Summary

Hologic (NASDAQ: HOLX) reported strong financial results for Q3 fiscal 2024, with revenue of $1,011.4 million, up 2.7% year-over-year. GAAP EPS was $0.82, and non-GAAP EPS was $1.06, both exceeding guidance. Organic revenue excluding COVID-19 grew 5.8% in constant currency. Key highlights include:

- Diagnostics revenue increased 0.3%, with Molecular Diagnostics up 2.8%
- Breast Health revenue rose 6.9%, driven by strong gantry sales and service
- Surgical revenue grew 5.9%
- Cash flow from operations was $405.7 million
- The company repurchased 1.4 million shares for $100 million

Hologic raised its full-year 2024 revenue guidance to $4,012 - $4,027 million and non-GAAP EPS guidance to $4.04 - $4.11. The company's strong performance demonstrates the durability of its broad portfolio across Diagnostics, Breast Health, and Surgical franchises.

Positive

• Revenue of $1,011.4 million increased 2.7%, exceeding guidance
• Non-GAAP EPS of $1.06, up 14% year-over-year
• Organic revenue excluding COVID-19 grew 5.8% in constant currency
• Breast Health revenue increased 6.9%, driven by strong gantry sales and service
• Surgical revenue grew 5.9%
• Cash flow from operations remained strong at $405.7 million
• Full-year 2024 revenue and EPS guidance raised

Negative

• Blood Screening revenue decreased 26.2%
• Skeletal Health revenue declined 29.9%

Insights

Financial Analyst

Hologic's Q3 fiscal 2024 results demonstrate solid performance and resilience in a challenging market environment. The company reported $1,011.4 million in revenue, a 2.7% increase year-over-year, or 3.1% in constant currency. Notably, organic revenue excluding COVID-19 grew by 5.8% in constant currency, indicating strong underlying business momentum.

Key highlights include:

• Diagnostics revenue (ex-COVID) grew 6.0% organically in constant currency, showcasing the strength of Hologic's core business.
• Breast Health revenue increased 6.9%, driven by strong gantry sales and service.
• Surgical revenue grew 5.9%, primarily due to solid sales of MyoSure and Fluent Fluid Management products.
• Non-GAAP EPS of $1.06, a 14.0% increase from the prior year.
• Strong cash flow from operations at $405.7 million.

The company's gross and operating margins showed significant improvement, with non-GAAP operating margin expanding 230 basis points to 31.2%. This margin expansion, coupled with strong revenue growth, indicates effective cost management and operational efficiency.

Hologic's balance sheet remains robust, with $2.4 billion in cash and equivalents and a low adjusted net leverage ratio of 0.1 times. This financial flexibility positions the company well for future growth opportunities and potential acquisitions.

The updated guidance for fiscal 2024 suggests continued momentum, with organic revenue excluding COVID-19 expected to grow between 5.2% and 5.6%. However, investors should note the potential impact of four fewer selling days in fiscal 2024 compared to 2023, which could create a headwind of over 100 basis points for the full year.

Overall, Hologic's Q3 results and outlook demonstrate the company's ability to navigate challenges and capitalize on its strengths in women's health and diagnostics markets.

Medical Research Analyst

Hologic's Q3 fiscal 2024 results highlight the company's strong position in the medical technology sector, particularly in women's health diagnostics and imaging. The 10.5% organic, constant currency growth in Molecular Diagnostics (excluding COVID-19) is particularly noteworthy, indicating robust demand for Hologic's core diagnostic offerings.

Key observations from a medical research perspective:

• The growth in BV CV/TV and non-COVID-19 respiratory assays suggests an expanding market for these diagnostic tools, potentially driven by increased awareness and testing protocols.
• The 6.9% growth in Breast Health revenue, primarily from gantry sales and service, indicates continued investment in breast cancer screening infrastructure, which is important for early detection and improved patient outcomes.
• The 5.9% growth in Surgical revenue, driven by MyoSure and Fluent Fluid Management products, suggests increasing adoption of minimally invasive gynecological procedures.

The acquisition of Endomagnetics is a strategic move that could enhance Hologic's portfolio in breast surgery localization and lymphatic tracing technologies. This acquisition aligns with the trend towards more precise and less invasive surgical techniques in breast cancer treatment.

However, the 29.9% decrease in Skeletal Health revenue and the temporary stop-ship of Horizon DXA systems due to a non-conformance issue are concerns that warrant attention. This highlights the importance of maintaining stringent quality control in medical devices and the potential impact of regulatory issues on revenue streams.

Looking ahead, Hologic's focus on its large Diagnostics installed base and the recovery of its Breast Health business suggest a strong foundation for future growth in critical areas of women's health. The company's ability to maintain growth in its core businesses while navigating the decline in COVID-19 related revenues demonstrates the resilience and diversification of its portfolio.

– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance –

– Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period –

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 29, 2024.

“In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Our strong fiscal quarter and year-to-date results continue to highlight the durable strength across our broad portfolio, with our Diagnostics (ex-COVID), Breast Health, and Surgical franchises delivering at or above our expectations. We are excited to finish fiscal 2024 strong as we continue to build for the long term.”

Recent Highlights

• Revenue of $1,011.4 million increased 2.7% for the quarter, or 3.1% in constant currency, primarily driven by higher sales in Molecular Diagnostics, Breast Imaging, and Surgical.
  • Excluding COVID-19 revenues, total organic revenue grew 5.5%, or 5.8% on a constant currency basis.
• Diagnostics revenue increased 0.3%, or 0.7% in constant currency, primarily driven by higher Molecular Diagnostics sales, partially offset by lower sales of COVID-19 assays compared to the prior year period.
  • Excluding COVID-19 revenues, Diagnostics revenue grew 6.0% on an organic, constant currency basis.
  • Molecular Diagnostics revenue grew 2.8%, or 3.1% in constant currency, primarily driven by higher sales of BV CV/TV and non-COVID-19 respiratory assays compared to the prior year period.
  • Excluding COVID-19 revenues, Molecular Diagnostics revenue grew 10.5% on an organic, constant currency basis.
• Breast Health revenue increased 6.9%, or 7.1% in constant currency, primarily driven by strong gantry sales and service.
  • Excluding SSI, Breast Health revenue increased 7.9%, or 8.2% in constant currency.
• Surgical revenue grew 5.9%, or 6.2% in constant currency, primarily driven by solid sales of MyoSure and Fluent Fluid Management products.
• Cash flow from operations remained strong in the third quarter at $405.7 million.
• Repurchased 1.4 million shares for $100 million.
• Closed the acquisition of Endomagnetics on July 25, 2024, which develops and sells breast surgery localization and lymphatic tracing technologies.

Key financial results for the fiscal third quarter shown in the table below:

	GAAP						Non-GAAP
	Q3’24		Q3’23		Change Increase (Decrease)		Q3’24		Q3’23		Change Increase (Decrease)
Revenues	1,011.4		984.4		2.7%		1,011.4		984.4		2.7%
Gross Margin	55.4%		37.3%		1,810 bps		61.1%		60.8%		30 bps
Operating Expenses	316.3		366.1		(13.6%)		302.8		313.9		(3.5%)
Operating Margin	24.1%		0.1%		2,400 bps		31.2%		28.9%		230 bps
Net Margin	19.2%		(4.1%)		2,330 bps		24.8%		23.5%		130 bps
Diluted EPS	$0.82		($0.16)		612.5%		$1.06		$0.93		14.0%

Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Our fiscal third quarter organic revenue results exclude the divested Blood Screening and SSI ultrasound imaging businesses. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition.

Revenue Detail

					Increase/(Decrease)
$ in millions	Q3’24		Q3’23		Global Reported Change		Global Constant Currency Change		U.S. Reported Change		International Reported Change		International Constant Currency Change
Diagnostics
Cytology and Perinatal	$122.2		$126.8		(3.6%)		(2.9%)		(8.0%)		4.1%		5.9%
Molecular Diagnostics	$310.7		$302.2		2.8%		3.1%		2.2%		5.2%		6.6%
Blood Screening	$7.9		$10.7		(26.2%)		(26.2%)		(26.2%)		N/A		N/A
Total Diagnostics	$440.8		$439.7		0.3%		0.7%		(1.2%)		4.7%		6.3%
Organic Diagnostics ex. COVID-19	$394.9		$374.2		5.5%		6.0%		4.0%		10.1%		11.7%
Breast Health
Breast Imaging	$309.2		$286.1		8.1%		8.3%		8.9%		5.3%		6.5%
Interventional Breast Solutions	$75.8		$74.2		2.2%		2.5%		1.5%		4.5%		6.2%
Total Breast Health	$385.0		$360.3		6.9%		7.1%		7.3%		5.1%		6.4%
GYN Surgical	$166.6		$157.3		5.9%		6.2%		2.4%		18.8%		19.8%
Skeletal Health	$19.0		$27.1		(29.9%)		(29.7%)		(25.6%)		(37.0%)		(36.2%)
Total	$1,011.4		$984.4		2.7%		3.1%		2.0%		5.1%		6.4%
Organic Revenue (definition above)	$1,003.0		$969.6		3.4%		3.8%		2.4%		6.9%		8.3%
Organic Revenue ex. COVID-19	$965.0		$914.8		5.5%		5.8%		4.3%		9.4%		10.8%

Other Financial Highlights

• U.S. revenue of $765.3 million increased 2.0%. International revenue of $246.1 million increased 5.1%, or 6.4% in constant currency.
• GAAP gross margin of 55.4% increased 1,810 basis points primarily due to lower impairment charges, driven by prior year period charges for intangible assets and equipment from the Mobidiag acquisition and SSI ultrasound imaging assets. Non-GAAP gross margin of 61.1% increased 30 basis points primarily due to an increase in sales compared to the prior year period.
• GAAP operating margin of 24.1% increased 2,400 basis points primarily due to lower impairment charges, driven by prior year period charges for intangible assets and equipment from the Mobidiag acquisition and SSI ultrasound imaging assets, as well as higher revenue and lower operating expenses. Non-GAAP operating margin of 31.2% increased 230 basis points, primarily due to higher revenue and lower operating expenses compared to the prior year period.
• GAAP net income of $194.5 million increased 580.2% and non-GAAP net income of $250.7 million increased 8.4%. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was $338.5 million, an increase of 8.5%.
• COVID-19 revenues, which consist of COVID-19 assay revenue of $13.3 million, and other COVID-19 related revenue plus revenue from discontinued products of $24.7 million, decreased (30.4%) in constant currency.
• Total principal debt outstanding at the end of the third quarter was $2.56 billion. The Company ended the quarter with cash and equivalents of $2.4 billion, and an adjusted net leverage ratio (net debt over EBITDA) of 0.1 times.
• On a trailing 12-month basis, adjusted Return on Invested Capital (ROIC) was 14.1%, a decrease of (10) basis points compared to the prior year period.

Financial Guidance for the Fourth Quarter and Full-Year Fiscal 2024

“Hologic delivered another strong financial performance in our fiscal third quarter of 2024, underscored by another quarter of sequential improvement in our operating margin and strong cash flow,” said Karleen Oberton, Hologic’s Chief Financial Officer. “As expected, the quality of our earnings continues to improve as we continue to capitalize on our large Diagnostics installed base and our Breast Health business returns to strength. We are on track for a strong finish to fiscal 2024.”

Hologic’s financial guidance for the fourth quarter and full year 2024 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.75%, and diluted shares outstanding of approximately 238 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2024 as in fiscal 2023. Organic revenue guidance for fiscal 2024 is in constant currency and excludes the divested Blood Screening, SSI ultrasound imaging, and Endomagnetics businesses. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition. Organic revenue excluding COVID-19 is in constant currency and is organic revenue excluding COVID-19 assay revenue, COVID-19 related revenue, and discontinued product sales in Diagnostics.

	Current Guidance*				Previous Guidance
	Guidance $	Reported % Increase (Decrease)	Constant Currency % Increase (Decrease)	Organic excluding COVID-19 % Increase	Guidance $
Fiscal 2024
Revenue	$4,012 - $4,027	(0.4%) to (0.1%)	(0.5%) to (0.1%)	5.2% to 5.6%	$4,000 - $4,050
GAAP EPS	$3.37 - $3.44	84.2% to 88.0%			$3.45 - $3.55
Non-GAAP EPS	$4.04 - $4.11	2.0% to 3.8%			$4.02 - $4.12
Q4 2024
Revenue	$970 - $985	2.6% to 4.2%	2.9% to 4.5%	5.0% to 6.6%
GAAP EPS	$0.80 - $0.87	116.2% to 135.1%
Non-GAAP EPS	$0.97 - $1.04	9.0% to 16.9%
*Fiscal 2024 has four fewer selling days compared to fiscal 2023. Factored into our guidance, we estimate the impact of the four fewer selling days to be a headwind of more than 100 bps for the full year. Fiscal 2024 and Q4 guidance incorporates Q3 performance, the addition of Endomagnetics, and impact from the temporary stop-ship of Horizon DXA systems (Skeletal) due to a non-conformance issue.

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; adjusted EBITDA; adjusted net leverage ratio and adjusted ROIC. Organic revenue for the fiscal third quarter of 2024 excludes the divested Blood Screening and SSI ultrasound imaging businesses. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. Organic revenue excluding COVID-19 revenues is organic revenue less COVID-19 assay revenue, COVID-19 related sales of instruments, collection kits and ancillaries, COVID-19 related revenue from Diagenode and Mobidiag, as well as COVID-19 related license revenue, and revenues from discontinued products in Diagnostics. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets; (ii) the impairment of goodwill and intangible assets and equipment and the loss to record assets held-for-sale to fair value less costs to sell; (iii) adjustments to record contingent consideration at fair value; (iv) charges to write-off inventory for a product line discontinuance; (v) restructuring charges, facility closure and consolidation charges (including accelerated depreciation), and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services); (vi) transaction related expenses for acquisitions; (vii) third-party expenses incurred related to the implementation of the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products; (viii) debt extinguishment losses and related transaction costs; (ix) unrealized (gains) losses on the mark-to-market of foreign currency contracts to hedge operating results for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the impacts related to internal restructurings and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest income/expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines its adjusted net leverage ratio as the principal amount of its debt net of cash and cash equivalents, divided by its adjusted EBITDA for the last four quarters. The Company defines its adjusted ROIC as its non-GAAP operating income for a trailing twelve months tax effected by its non-GAAP effective tax rate divided by the sum of its average net debt and stockholders’ equity, which is adjusted to exclude the effects of goodwill and intangible assets and equipment impairment charges.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company's definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items many of which can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Hologic's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic's business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Conference Call and Webcast

Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the third quarter of fiscal 2024. Interested participants may listen to the call by dialing 888-394-8218 (in the U.S. and Canada) or +1 773-305-6853 (for international callers) and referencing access code 5372869. Participants may also click to join. Participants should dial in 5-10 minutes before the call begins. The Company will also provide a live and replay webcast of the call at hologic.com/investors. The replay of the call will be available approximately two hours after the call ends through Friday, August 23, 2024.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include, without limitation: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, such as inflation, bank failures, rising interest rates and availability of capital markets, geopolitical conflicts, wars, other economic disruptions and U.S. and global recession concerns, on the Company’s customers and suppliers and on the Company’s business, financial condition, results of operations and cash flows and the Company’s ability to draw down its revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulation and tariffs, that may adversely impact the cost and sale of the Company’s products in certain countries, or increase the costs the Company may incur to purchase materials, parts and equipment from its suppliers; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions the Company may complete in the future; the development of new competitive technologies and products and competition; the Company’s ability to predict accurately the demand for its products, and products under development and to develop strategies to address markets successfully; continued demand for the Company’s COVID-19 assays; potential cybersecurity threats and targeted computer crime; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at the Company’s manufacturing facilities, or the failure to secure alternative suppliers if any of the Company’s sole source third-party manufacturers fail to supply the Company; the ability to consolidate certain of the Company’s manufacturing and other operations on a timely basis and within budget, without disrupting its business and to achieve anticipated cost synergies related to such actions; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the ability to obtain and maintain regulatory approvals and clearances for the Company’s products, including the implementation of the European Union Medical Device Regulations and In Vitro Diagnostic Regulation requirements, and to maintain compliance with complex and evolving regulations and quality standards, as well as the uncertainty of costs required to obtain and maintain compliance with such regulatory and quality matters; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; the effect of any future public health crises, including the timing, scope and effect of U.S. and international governmental, regulatory, fiscal, monetary and public health responses to such crises; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; cost and expenses of investigative and legal proceedings and compliance risks; potential negative impacts resulting from climate change or other environmental, social and governance and sustainability related matters; and technical innovations that could render products marketed or under development by the Company obsolete.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

HOLOGIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and per share data)
	Three Months Ended								Nine Months Ended
	June 29, 2024				July 1, 2023				June 29, 2024				July 1, 2023
Revenues:
Product	$	811.2			$	799.1			$	2,467.2			$	2,522.9
Service and other		200.2				185.3				575.1				562.2
Total revenues		1,011.4				984.4				3,042.3				3,085.1
Cost of revenues:
Product		298.2				291.0				913.9				879.3
Amortization of acquired intangible assets		44.4				51.6				134.9				159.3
Impairment of intangible assets and equipment		13.3				179.5				39.2				179.5
Service and other		95.2				94.8				284.2				295.8
Gross profit		560.3				367.5				1,670.1				1,571.2
Operating expenses:
Research and development		64.1				72.6				205.5				221.4
Selling and marketing		146.3				149.8				439.4				455.7
General and administrative		94.0				90.2				306.2				299.5
Amortization of acquired intangible assets		5.3				7.1				24.3				21.9
Impairment of intangible assets and equipment		0.4				44.3				5.6				44.3
Contingent consideration - fair value adjustments		—				—				1.7				(12.4	)
Restructuring charges		6.2				2.1				34.8				4.9
Total operating expenses		316.3				366.1				1,017.5				1,035.3
Income from operations		244.0				1.4				652.6				535.9
Interest income		28.4				32.5				80.3				84.6
Interest expense		(31.9	)			(27.7	)			(90.2	)			(83.0	)
Other income (expense), net		0.2				5.9				0.8				(7.0	)
Income before income taxes		240.7				12.1				643.5				530.5
Provision for income taxes		46.2				52.6				32.6				165.1
Net income (loss)	$	194.5			$	(40.5	)		$	610.9			$	365.4
Net income (loss) per common share:
Basic	$	0.83			$	(0.16	)		$	2.58			$	1.48
Diluted	$	0.82			$	(0.16	)		$	2.57			$	1.47
Weighted average number of shares outstanding:
Basic		234,604				246,908				236,373				247,319
Diluted		236,466				246,908				238,081				249,393

HOLOGIC, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions)
	June 29, 2024				September 30, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	2,439.1			$	2,722.5
Accounts receivable, net		628.5				625.6
Inventory		665.5				617.6
Other current assets		263.9				206.9
Assets held-for-sale - current assets		—				11.9
Total current assets		3,997.0				4,184.5
Property, plant and equipment, net		528.8				517.0
Goodwill and intangible assets		3,978.7				4,169.9
Other assets		385.6				267.9
Total assets	$	8,890.1			$	9,139.3
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt	$	37.5			$	287.0
Accounts payable and accrued liabilities		745.9				712.9
Deferred revenue		219.0				199.2
Assets held-for-sale - current liabilities		—				8.2
Total current liabilities		1,002.4				1,207.3
Long-term debt, net of current portion		2,505.6				2,531.2
Deferred income taxes		17.8				20.2
Other long-term liabilities		413.4				363.7
Total stockholders' equity		4,950.9				5,016.9
Total liabilities and stockholders’ equity	$	8,890.1			$	9,139.3

HOLOGIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In millions)
	Nine Months Ended
	June 29, 2024				July 1, 2023
OPERATING ACTIVITIES
Net income	$	610.9			$	365.4
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		75.2				66.7
Amortization of acquired intangible assets		159.2				181.2
Stock-based compensation expense		69.1				60.6
Deferred income taxes		(52.3	)			(100.2	)
Intangible asset and equipment impairment charges		44.8				223.8
Contingent consideration fair value adjustments		1.7				(12.4	)
Other adjustments and non-cash items		32.4				30.6
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
Accounts receivable		(2.5	)			(51.0	)
Inventories		(47.1	)			(48.5	)
Prepaid income taxes		(73.9	)			15.3
Prepaid expenses and other assets		(4.2	)			24.6
Accounts payable		26.5				(20.3	)
Accrued expenses and other liabilities		58.5				10.7
Deferred revenue		19.9				46.0
Net cash provided by operating activities		918.2				792.5
INVESTING ACTIVITIES
Sale of business, net of cash disposed		(31.3	)			—
Capital expenditures		(56.0	)			(55.5	)
Proceeds from the Department of Defense		—				20.5
Increase in equipment under customer usage agreements		(43.9	)			(42.2	)
Strategic investments		(42.5	)			(10.0	)
Purchase of intellectual property		(10.0	)			—
Other activity		(1.6	)			(8.9	)
Net cash used in investing activities		(185.3	)			(96.1	)
FINANCING ACTIVITIES
Repayment of long-term debt		(278.1	)			(11.3	)
Payment of contingent consideration		(2.6	)			(7.6	)
Payment of deferred acquisition consideration		—				(0.8	)
Repurchases of common stock		(776.8	)			(263.6	)
Proceeds from issuance of common stock pursuant to employee stock plans		25.2				37.7
Payment of minimum tax withholdings on net share settlements of equity awards		(16.6	)			(23.7	)
Payments under finance lease obligations		(2.9	)			(3.3	)
Net cash used in financing activities		(1,051.8	)			(272.6	)
Effect of exchange rate changes on cash and cash equivalents		2.3				1.7
Net (decrease) increase in cash and cash equivalents		(316.6	)			425.5
Cash and cash equivalents, beginning of period*		2,755.7				2,339.5
Cash and cash equivalents, end of period	$	2,439.1			$	2,765.0
*Includes $33.2 million of cash recorded in assets held-for-sale - current assets as of September 30, 2023.

HOLOGIC, INC.
RECONCILIATION OF GAAP TO NON-GAAP RESULTS
(Unaudited)
(In millions, except earnings per share)
Reconciliation of GAAP Revenue to Organic Revenue
	Three Months Ended								Nine Months Ended
	June 29, 2024				July 1, 2023				June 29, 2024				July 1, 2023
Consolidated GAAP Revenue	$	1,011.4			$	984.4			$	3,042.3			$	3,085.1
Less: Blood Screening revenue		(7.9	)			(10.7	)			(22.8	)			(28.5	)
Less: SSI revenue		(0.5	)			(4.1	)			(2.3	)			(14.7	)
Organic Revenue	$	1,003.0			$	969.6			$	3,017.2			$	3,041.9
Less: COVID-19 Assays		(13.3	)			(28.7	)			(63.4	)			(226.8	)
Less: COVID-19 Related Revenue*		(24.7	)			(25.8	)			(79.1	)			(88.6	)
Less: Discontinued Product Revenue		—				(0.3	)			(0.4	)			(2.9	)
Organic Revenue excluding COVID-19	$	965.0			$	914.8			$	2,874.3			$	2,723.6
*Revenues estimated to be related to COVID assay sales for instruments, collection kits and ancillaries.

	Three Months Ended								Nine Months Ended
	June 29, 2024				July 1, 2023				June 29, 2024				July 1, 2023
Gross Profit:
GAAP gross profit	$	560.3			$	367.5			$	1,670.1			$	1,571.2
Adjustments:
Amortization of acquired intangible assets (1)		44.4				51.6				134.9				159.3
Impairment of intangible assets and equipment (14)		13.3				179.5				39.2				179.5
Product line discontinuance (13)		—				—				7.1				—
Integration/consolidation costs (3)		—				(0.2	)			—				(0.1	)
Non-GAAP gross profit	$	618.0			$	598.4			$	1,851.3			$	1,909.9
Gross Margin Percentage:
GAAP gross margin percentage		55.4	%			37.3	%			54.9	%			50.9	%
Impact of adjustments above		5.7	%			23.5	%			6.0	%			11.0	%
Non-GAAP gross margin percentage		61.1	%			60.8	%			60.9	%			61.9	%
Operating Expenses:
GAAP operating expenses	$	316.3			$	366.1			$	1,017.5			$	1,035.3
Adjustments:
Amortization of acquired intangible assets (1)		(5.3	)			(7.1	)			(24.3	)			(21.9	)
Impairment of intangible assets and equipment (14)		(0.4	)			(44.3	)			(5.6	)			(44.3	)
Transaction expenses (4)		(1.6	)			—				(3.4	)			(0.3	)
Contingent consideration adjustments (7)		—				—				(1.7	)			12.4
Integration/consolidation costs (3)		—				—				—				(0.5	)
Purchased research and development asset charge (16)		—				—				(10.0	)			—
MDR expenses (2)		—				(0.2	)			—				(1.3	)
Legal related settlements (11)		—				1.0				—				(1.3	)
Restructuring charges (3)		(6.2	)			(2.1	)			(34.8	)			(4.9	)
Non-income tax benefit/charge, net (5)		—				0.5				—				(2.9	)
Non-GAAP operating expenses	$	302.8			$	313.9			$	937.7			$	970.3
Operating Margin:
GAAP income from operations	$	244.0			$	1.4			$	652.6			$	535.9
Adjustments to gross profit as detailed above		57.7				230.9				181.2				338.7
Adjustments to operating expenses as detailed above		13.5				52.2				79.8				65.0
Non-GAAP income from operations	$	315.2			$	284.5			$	913.6			$	939.6
Operating Margin Percentage:
GAAP income from operations margin percentage		24.1	%			0.1	%			21.5	%			17.4	%
Impact of adjustments above		7.1	%			28.8	%			8.5	%			13.1	%
Non-GAAP operating margin percentage		31.2	%			28.9	%			30.0	%			30.5	%

Pre-Tax Income:
GAAP pre-tax earnings	$	240.7			$	12.1			$	643.5			$	530.5
Adjustments to pre-tax earnings as detailed above		71.2				283.1				261.0				403.7
Debt extinguishment loss (6)		—				—				0.4				—
Unrealized losses (gains) on forward foreign currency contracts (8)		0.5				(0.9	)			6.2				19.0
Non-GAAP pre-tax income	$	312.4			$	294.3			$	911.1			$	953.2
Net Income (loss):
GAAP net income (loss)	$	194.5			$	(40.5	)		$	610.9			$	365.4
Adjustments:
Amortization of acquired intangible assets (1)		49.7				58.7				159.2				181.2
Impairment of intangible assets and equipment (14)		13.7				223.8				44.8				223.8
Restructuring and integration/consolidation costs (3)		6.2				1.9				34.8				5.5
Purchased research and development asset charge (16)		—				—				10.0				—
Product line discontinuance (13)		—				—				7.1				—
MDR expenses (2)		—				0.2				—				1.3
Debt extinguishment loss (6)		—				—				0.4				—
Legal related settlements (11)		—				(1.0	)			—				1.3
Transaction expenses (4)		1.6				—				3.4				0.3
Contingent consideration adjustments (7)		—				—				1.7				(12.4	)
Unrealized losses (gains) on forward foreign currency contracts (8)		0.5				(0.9	)			6.2				19.0
Non-income tax (benefit) charge, net (5)		—				(0.5	)			—				2.9
Worthless stock deduction (15)		—				—				(107.2	)			—
Income tax related items (9)		3.7				42.7				15.6				62.3
Income tax effect of reconciling items (12)		(19.2	)			(53.1	)			(55.7	)			(85.7	)
Non-GAAP net income	$	250.7			$	231.3			$	731.2			$	764.9
Net Income (Loss) Percentage:
GAAP net income (loss) percentage		19.2	%			(4.1	)%			20.1	%			11.8	%
Impact of adjustments above		5.6	%			27.6	%			3.9	%			13.0	%
Non-GAAP net income percentage		24.8	%			23.5	%			24.0	%			24.8	%
Earnings (Loss) per Share:
GAAP income (loss) per share - Diluted	$	0.82			$	(0.16	)		$	2.57			$	1.47
Adjustment to net income (loss) (as detailed above)		0.24				1.09				0.50				1.60
Non-GAAP earnings per share – diluted (10)	$	1.06			$	0.93			$	3.07			$	3.07
Adjusted EBITDA:
Non-GAAP net income	$	250.7			$	231.3			$	731.2			$	764.9
Interest expense (income), net		3.5				(4.8	)			9.9				(1.6	)
Provision for income taxes		61.7				63.1				179.9				188.3
Depreciation expense, not adjusted above		22.6				22.3				68.0				66.7
Adjusted EBITDA	$	338.5			$	311.9			$	989.0			$	1,018.3

Explanatory Notes to Reconciliations:
(1)		To reflect non-cash expenses attributable to the amortization of acquired intangible assets.
(2)		To reflect the exclusion of third-party expenses incurred to obtain compliance with the European Medical Device Regulation requirement for the Company's existing products for which it already had FDA approval and/or CE mark.
(3)		To reflect restructuring charges, and certain costs associated with the Company’s integration and facility consolidation plans, which primarily include severance, retention and transfer costs, as well as costs incurred to integrate acquisitions, including consulting, legal and tax fees. In addition, this category includes additional expenses, primarily accelerated depreciation and an impairment on a lease asset incurred in fiscal 2024 related to closing Mobidiag’s Finland and France Facilities.
(4)		To reflect expenses incurred with third parties related to acquisitions prior to when such transactions are completed. These expenses primarily comprise legal, consulting and due diligence fees.
(5)		To reflect the net impact of establishing a non-income tax loss contingency related to prior years and the settlement of a prior year non-income tax audit.
(6)		To reflect a debt extinguishment loss for the prepayment of debt under the Credit Agreement in first quarter of fiscal 2024.
(7)		To reflect an adjustment to the contingent consideration liability related to the Acessa Health acquisition, which was payable upon meeting defined revenue growth metrics.
(8)		To reflect non-cash unrealized gains and losses on the mark-to market on outstanding forward foreign currency contracts, which have not been designated for hedge accounting.
(9)		To reflect the net impact of income tax reserves from the expiration of the statute of limitations, and non-recurring income tax charges and benefits.
(10)		Non-GAAP earnings per share was calculated based on 236,466 and 238,081 weighted average diluted shares outstanding for the three and nine months ended June 29, 2024, respectively, and 249,107 and 249,393 for the three and nine months ended July 1, 2023, respectively.
(11)		To reflect net charges and benefits from legal related settlements.
(12)		To reflect the tax effects of non-GAAP reconciling items, excluding specific income tax related items separately stated in Note 9 and the worthless stock deduction referred to in Note 15. Amounts are calculated using the effective tax rate in the jurisdiction to which the adjustment relates.
(13)		To reflect the write-off of inventory and charges for non-cancellable purchase orders related to a product line discontinuance in the Diagnostics division.
(14)		To reflect an impairment charge for an in-process research and development intangible asset acquired in the Mobidiag acquisition recorded in the first quarter of fiscal 2024 and an impairment charge related to intangible assets from the Focal acquisition recorded in the second and third quarters of fiscal 2024, respectively. To reflect impairment charges for intangible assets and equipment acquired in the Mobidiag acquisition and impairment of our SSI ultrasound imaging assets during the third quarter of fiscal 2023.
(15)		To reflect the discrete tax benefit related to a worthless stock deduction on the investment in one of the Company's international subsidiaries.
(16)		To reflect the purchase of an intangible asset to be used in a research and development project that has no future alternative use.

Reconciliation of GAAP to non-GAAP EPS Guidance:
	Guidance Range				Guidance Range
	Quarter Ending September 28, 2024				Year Ending September 28, 2024
	Low		High		Low		High
GAAP Net Income Per Share	$0.80		$0.87		$3.37		$3.44
Amortization of acquired intangible assets	0.20		0.20		0.87		0.87
Impairment of Intangible asset	-		-		0.19		0.19
Restructuring, Integration and Other charges	0.01		0.01		0.25		0.25
Non-operating charges	-		-		0.03		0.03
Worthless stock deduction	-		-		(0.45)		(0.45)
Tax Impact of Exclusions and related items	(0.04)		(0.04)		(0.22)		(0.22)
Non-GAAP Net Income Per Share	$0.97		$1.04		$4.04		$4.11

Return on Invested Capital (ROIC) Reconciliation of Net Income to ROIC:
	Trailing Twelve Months Ended June 29, 2024
Adjusted Net Operating Profit After Tax
GAAP net income	$	701.5
Adjustments to GAAP net income		249.0
Non-GAAP net income	$	950.5
Non-GAAP provision for income taxes		233.9
Non-GAAP interest expense		118.2
Non-GAAP other income		(121.3	)
Adjusted net operating profit before tax	$	1,181.3
Non-GAAP average effective tax rate (1)		19.8	%
Adjusted net operating profit after tax	$	948.0
Average Net Debt plus Average Stockholders' Equity (2)
Average total debt	$	2,682.1
Less: Average cash and cash equivalents		(2,602.0	)
Average net debt	$	80.1
Average stockholders' equity (3)		6,645.8
Average net debt plus average stockholders' equity	$	6,725.9
Adjusted Return on Invested Capital		14.1	%
Adjusted ROIC (adjusted net operating profit after tax above divided by average net debt plus average stockholders’ equity)

(1)		ROIC is presented on a TTM basis; non-GAAP effective tax rate for the entire trailing twelve-month period was 19.75%.
(2)		Calculated using the average of the balances as of June 29, 2024, and July 1, 2023.
(3)		For Adjusted ROIC, stockholder's equity is adjusted (increased) to eliminate the effect of the impairment of intangible assets of $32.2 million in fiscal 2014, the impairment of goodwill of $685.7 million and an IPR&D asset of $46.0 million in fiscal 2018, the impairment of intangible assets and equipment of $685.4 million in fiscal 2019, the impairment of intangible assets and equipment of $30.2 million in fiscal 2020, the impairment of intangible assets of $45.1 million in fiscal 2022, the impairment of intangible assets and equipment of $223.8 million in fiscal 2023 and the impairment of an intangible asset of $4.3 million in the first quarter of fiscal 2024, $26.8 million in the second quarter of fiscal 2024 and $13.7 million in the third quarter of fiscal 2024. The impact of the intangible asset impairment charges is reflected in net of tax.

	As of June 29, 2024
	Net Leverage Ratio:
Total principal debt	$	2,556.9
Total cash and cash equivalents	$	(2,439.1	)
Net principal debt	$	117.8
EBITDA for the last four quarters	$	1,277.3
Net Leverage Ratio		0.1

Other Supplemental Information:
		Three Months Ended						Nine Months Ended
		June 29, 2024			July 1, 2023			June 29, 2024			July 1, 2023
Geographic Revenues
United States		75.7	%		76.2	%		74.9	%		75.9	%
Europe		12.6	%		13.1	%		13.4	%		13.9	%
Asia-Pacific		6.4	%		6.4	%		6.4	%		6.2	%
Rest of World		5.3	%		4.3	%		5.3	%		4.0	%
Total Revenues		100.0	%		100.0	%		100.0	%		100.0	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729445441/en/

Ryan Simon

Vice President, Investor Relations

ryan.simon@hologic.com

(858) 410-8514

Ryan McDowell

Director, Investor Relations

ryan.mcDowell@hologic.com

(508) 263-8891

Source: Hologic, Inc.

FAQ

What was Hologic's (HOLX) revenue in Q3 fiscal 2024?

Hologic's revenue in Q3 fiscal 2024 was $1,011.4 million, an increase of 2.7% compared to the same period last year.

How much did Hologic's (HOLX) Breast Health segment grow in Q3 2024?

Hologic's Breast Health segment revenue increased by 6.9%, or 7.1% in constant currency, primarily driven by strong gantry sales and service.

What was Hologic's (HOLX) non-GAAP EPS for Q3 2024?

Hologic's non-GAAP diluted EPS for Q3 2024 was $1.06, representing a 14% increase compared to the prior year period.

How much did Hologic (HOLX) spend on share repurchases in Q3 2024?

Hologic repurchased 1.4 million shares for $100 million during Q3 fiscal 2024.